Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Cell Therapy News
Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Subscribe|Follow Us On
IL-9 Signaling Redirects CAR T Cell Fate toward CD8+ Memory and CD4+ Cycling States, Enhancing Antitumor Efficacy
[Immunity] Investigators demonstrated that endowing CAR T cells with ectopic interleukin (IL)-9 signaling by co-expressing an IL-9 receptor rewires CAR T cell fate under antigen stress to enhance antitumor efficacy.
In Situ Chimeric Antigen Receptor Macrophage Therapy via Co-Delivery of mRNA and Immunostimulant
[ACS Nano ] Researchers reported an in situ CAR-macrophage therapy via codelivery of mRNA and immunostimulant. By leveraging lipid nanoparticles designed to selectively transfect tumor-associated macrophages, they circumvent extensive ex vivo manipulation and achieve robust CAR expression directly within the tumor microenvironment.
A Yeast Surface Display Platform for Characterizing CAR T Cell Responses to Cancer Antigens
[Nature Communications] The authors present an engineered yeast-based antigen system for the simulation of cancer cells with precise regulation of surface-antigen densities, providing a tool for controlled activation of CAR T cells and systematic assessment of antigen density effects.
Multiplex Gene-Editing Strategy to Engineer Allogeneic EGFR-Targeting CAR T-Cells with Improved Efficacy against Solid Tumors
[Nature Communications] Scientists described a multifaceted approach to engineer allogeneic CAR T-cells resistant to both biochemical and immunological inhibitory signaling using an adenine base editor and a CRISPR-Cas12b nuclease.
Anti-BCMA/CD19 CAR T Cell Therapy in Patients with Refractory Generalized Myasthenia Gravis: A Single-Arm, Phase I Trial
[EClinicalMedicine] Researchers developed autologous anti-B-cell maturation antigen (BCMA) and CD19 bispecific CAR T cells to evaluate the safety and efficacy in refractory myasthenia gravis.
Anti-uPAR CAR T Cells Reverse and Prevent Aging-Associated Defects in Intestinal Regeneration and Fitness
[Nature Aging] Scientists have previously identified the urokinase plasminogen activator receptor (uPAR) as a senescence-associated protein and have developed CAR T cells that can efficiently target it. Here, they identified the accumulation of mostly epithelial uPAR-positive cells in the aging gut and uncovered their detrimental impact on intestinal stem cells function in aging.
Base Edited “Universal” Donor CAR T-Cell Strategies for Acute Myeloid Leukaemia
[Leukemia] Investigators reported that monotherapy using base-edited “universal” donor CAR T cells against CD33, CLL-1, or CD7 delivered inhibition of acute myeloid leukaemia in immunodeficient mice when antigen expression was homogenous. Still, the combined use of BE-CAR33 and BE-CARCLL-1 T cells was required to address heterogeneous CLL-1-/+CD33-/+ disease.
Targeting Orthotopic and Metastatic Pancreatic Cancer with Allogeneic Stem Cell-Engineered Mesothelin-Redirected CAR-NKT Cells
[Proceedings of The National Academy of Sciences of The United States of America] Researchers developed an off-the-shelf immunotherapy using gene-engineered natural killer T cells derived from stem cells called Allo15MCAR-NKT cells.
Bone Marrow Blasts- and Modified EASIX-Guided Risk Stratification for Coagulopathy and Outcomes after CAR-T Therapy in Relapsed/Refractory B-ALL
[Thrombosis Research] An effective CAR-T-associated coagulopathy (CARAC) risk prediction and stratification model was established. High-risk CARAC patients, particularly CARAC-disseminated intravascular coagulation, were associated with significantly worse outcomes.
IL-21-Reprogrammed Vδ1 T Cells Exert Killing against Solid Tumors Which Is Enhanced by CAR Arming for Off-the-Shelf Immunotherapy
[Oncoimmunology] When engineered with a CAR, Vδ1 T cells exhibited further enhanced anti-tumor efficacy in an immunodeficient NRG xenograft model of human ovarian cancer. These findings highlight K562-mb-IL-21 expanded peripheral blood Vδ1 T cells as a promising ‘off-the-shelf’ allogeneic therapy for solid tumors.
Evaluation of Dasatinib and Ponatinib for the Control of CD123 CAR T Cell Functionalities
[Molecular Therapy Oncology] Investigators evaluated the capacity of two tyrosine kinase inhibitors, dasatinib and ponatinib, to reversibly inhibit CAR T cell functions.
CAR-T Cell Exhaustion in B Cell Lymphoma: Current Status, Mechanisms, and Potential Solutions
[Molecular Therapy Oncology] The authors discuss the current situation of CAR-T therapies in the clinical treatment of lymphoma patients, the mechanisms of CAR-T cell exhaustion, and potential strategies to overcome CAR-T cell exhaustion, thereby bringing hope to improve therapeutic outcomes for lymphoma patients.
Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.
